Frédéric André De Ceuninck

Title: Innovator Frédéric André De Ceuninck: A Trailblazer in Osteoarthritis Treatment

Introduction

Frédéric André De Ceuninck is a prominent inventor based in Paris, France. With a total of six patents to his name, De Ceuninck has made significant contributions to the pharmaceutical field, particularly in the treatment of osteoarthritis.

Latest Patents

One of De Ceuninck's latest innovations involves the development of 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives. These compounds act as inhibitors of ADAMTS, a family of proteins linked to the degradation of cartilage. The invention documents methods for the production of these compounds, along with pharmaceutical compositions that utilize them. The approach not only focuses on the prophylaxis and treatment of inflammatory conditions but also addresses diseases that involve the degradation of cartilage and disruption of cartilage homeostasis.

Career Highlights

Throughout his career, Frédéric André De Ceuninck has collaborated with notable organizations, including Galapagos NV and Les Laboratoires Servier. His work has primarily centered on innovating treatments aimed at tackling debilitating conditions such as osteoarthritis.

Collaborations

In addition to his work with leading companies, De Ceuninck has effectively collaborated with esteemed colleagues, including Franck Laurent Brebion and Luke Jonathan Alvey. Their combined expertise has likely fostered advancements in drug development and innovative therapeutic strategies.

Conclusion

Frédéric André De Ceuninck stands out as a key inventor in the pharmaceutical industry, specifically in the quest to innovate treatments for osteoarthritis. With his continued dedication to developing new therapeutic compounds, he plays a vital role in enhancing the quality of life for those affected by degenerative joint diseases. His work exemplifies the transformative power of innovation in medicine.